Taysha Gene Therapies to Participate in Upcoming May Investor Healthcare Conferences
Taysha Gene Therapies (Nasdaq: TSHA) announced its participation in two virtual events: the 2021 RBC Capital Markets Global Healthcare Conference on May 19 at 3:05 PM ET and the Oppenheimer Rare & Orphan Disease Summit on May 21 at 4:35 PM ET. The discussions will involve key executives including RA Session II, Dr. Suyash Prasad, and Kamran Alam. Webcasts will be available in the Events & Media section of their corporate website for 60 days after the events.
- None.
- None.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference and a virtual presentation at the Oppenheimer Rare & Orphan Disease Summit.
Conference Details: |
||
Event: |
2021 RBC Capital Markets Global Healthcare Conference |
|
Date: |
Wednesday, May 19, 2021 |
|
Time: |
3:05 pm ET |
|
Format: |
Fireside chat |
|
Participants: |
RA Session II, President, Founder and CEO |
|
|
Dr. Suyash Prasad, Chief Medical Officer and Head of Research and Development |
|
|
Kamran Alam, Chief Financial Officer |
|
|
|
|
Event: |
Oppenheimer Rare & Orphan Disease Summit |
|
Date: |
Friday, May 21, 2021 |
|
Time: |
4:35 pm ET |
|
Format: |
Presentation |
|
Participants: |
RA Session II, President, Founder and CEO |
|
|
Dr. Suyash Prasad, Chief Medical Officer and Head of Research and Development |
|
|
Kamran Alam, Chief Financial Officer |
|
Webcasts for these conferences will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210512006057/en/
FAQ
What are the dates for Taysha's participation in the RBC Capital Markets Global Healthcare Conference?
What time does the Oppenheimer Rare & Orphan Disease Summit start?
Who will represent Taysha at the RBC Capital Markets Global Healthcare Conference?
Where can I watch the webcasts of Taysha's conference presentations?
What is Taysha Gene Therapies focused on?
